Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

CALIFORNIA: Six Recommended Measures to Prevent Hepatitis C for Young Injection-Drug Users


University of California, San Francisco (07.24.2013)

Researchers at the University of California San Francisco (UCSF) have come up with six measures to prevent hepatitis C virus (HCV) transmission among injection drug users. The measures resulted from the “U Find Out” (UFO) study, a 16-year UCSF injection drug use research project funded by the US National Institute on Drug Abuse and the Australian Government Department of Health and Aging. After examining various data sources, the researchers estimated 31,000 new HCV diagnoses occurred per year and pinpointed six areas for focusing prevention efforts. Although syringe exchange has worked, the researchers found that the virus lived a long time on surfaces and could contaminate drug-injection equipment in addition to syringes. As a result, they approved of expanding needle exchanges across the country, but recommended that all needle exchanges provided clean preparation equipment as well as the usual needles and syringes. The researchers also recommended HCV screening, testing, and counseling; risk reduction through interventions targeting the social and relational environment of injecting; interventions that provided breaks from or completely ended drug use; development of models to guide new hepatitis C treatments and vaccines; and combined interventions to end HCV risk and injecting drug use. The study also examined behaviors associated with users’ attempts to complete substance abuse programs. Although the injectors often failed the programs, the study showed that the more they tried to quit or take breaks from drugs, the higher the chances that they would succeed eventually. The researchers highlighted the value of taking breaks from drugs to reduce the risk of transmission and help end drug use, and disapproved of treatment programs that permanently banned injectors who failed as not being conducive to reducing disease exposure risks or ending the drug use. The full report, “Injection Drug Use and Hepatitis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention,” was published in a supplement to the journal Clinical Infectious Disease (2013; 57 [Suppl 2]: S32–S38).


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in July 29, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.